This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GNRX VanEck Vectors Generic Drugs ETF (GNRX) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About VanEck Vectors Generic Drugs ETF (NASDAQ:GNRX) 30 days 90 days 365 days Advanced Chart Get GNRX alerts:Sign Up Key Stats Today's Range$22.42▼$22.4250-Day Range$22.42▼$22.4252-Week Range$20.17▼$26.19Volume4 shsAverage Volume1,310 shsMarket Capitalization$3.36 millionAssets Under Management$3.36 millionDividend Yield0.04%Net Expense Ratio0.57%Aggregate RatingN/A ETF OverviewRead More… VanEck Vectors Generic Drugs ETF ExpensesTypeGNRXHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.54%0.53%Other Expenses2.44%0.30%0.48%0.42%0.51%Total Expense2.94%0.70%0.72%0.68%0.71%Fee Waiver-2.37%-0.45%-0.49%-0.29%-0.54%Net Expense0.57%0.61%0.63%0.62%0.60% Receive GNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Vectors Generic Drugs ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNRX ETF News HeadlinesAmplify Weight Loss Drug & Treatment ETF (THNR)August 4, 2024 | finance.yahoo.comVanEck Vectors Preferred Securities Ex Financials ETF declares monthly distribution of $0.1422December 4, 2023 | msn.comThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.May 22, 2025 | Priority Gold (Ad)GDIG ETF Stock Price HistoryNovember 10, 2023 | investing.comVanEck Announces Changes to ETF Product LineApril 18, 2023 | finance.yahoo.comVanEck AEX UCITS ETF (TDT)March 3, 2023 | investing.comSee More Headlines GNRX ETF - Frequently Asked Questions What other stocks do shareholders of VanEck Vectors Generic Drugs ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Vectors Generic Drugs ETF investors own include SLR Investment (SLRC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX) and Yamana Gold (AUY). Fund Details IssuerVan Eck Fund NameVanEck Vectors Generic Drugs ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNRX Inception Date1/12/2016 Fund ManagerHao-Hung (Peter) Liao, Guo Hua (Jason) Jin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkIndxx Global Generics & New Pharma Index CategorySector FocusHealth Care Development LevelBlended Development RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$3.36 million Average Daily Volume$591.00 Discount/Premium-0.42% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianThe Bank of New York Mellon Corporation DistributorVan Eck Securities Corporation Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCantor Fitzgerald Miscellaneous Outstanding Shares150,000BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report GNRX Sector ExposureGNRX Industry Exposure This page (NASDAQ:GNRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Vectors Generic Drugs ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Vectors Generic Drugs ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
